You are here

adcomm

FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer population

Fierce Pharma

Thu, 05/22/25 - 11:27 am

prostate cancer

FDA delays decision on Biohaven's rare disease drug filing, plans adcomm

Fierce Biotech

Thu, 05/15/25 - 11:02 am

FDA set to meet this month on COVID vaccines

BioPharma Dive

Wed, 05/7/25 - 10:54 pm

FDA adcomm reform talks heat up

Pharma Voice

Tue, 09/3/24 - 11:11 am